<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02264535</url>
  </required_header>
  <id_info>
    <org_study_id>Z-YXPU-ZS-IV4</org_study_id>
    <nct_id>NCT02264535</nct_id>
  </id_info>
  <brief_title>A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.</brief_title>
  <official_title>A Pilot Study for Ginkgolides Meglumine Injection Skin Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Kanion Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Kanion Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is designed to explore the optimal concentration and method of Ginkgolides
      Meglumine Injection skin testing and to evaluate the value of skin test in predicting any
      possible allergic reactions to Ginkgolides Meglumine Injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled in one of three groups with different doses to receive skin prick
      testing. Then they may be arranged to receive intradermal, subcutaneous injection or
      intravenous tests with different doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of allergic reaction and analyze all kinds of positive reactions after skin prick test with different doses of Ginkgolides Meglumine Injection.</measure>
    <time_frame>15-20 minutes after skin prick tests.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of allergic reaction and analyze all kinds of positive reactions after using intradermal tests of different doses of Ginkgolides Meglumine Injection.</measure>
    <time_frame>15-20 minutes after intradermal tests.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The specificity and sensitivity with the different doses.</measure>
    <time_frame>15-20 minutes after prick-puncture and intradermal tests, 72 hours after subcutaneous test.</time_frame>
    <description>Specificity (SPC) =TN/ (FP+TN); Sensitivity=TP/ (TP+FN). TP (true positive); TN (true negative); FP (false positive); FN (false negative). TP(true positive); TN(true negative); FP(false positive); FN(false negative).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment will be based on adverse event reports, electrocardiogram, physical examinations and clinical laboratory tests.</measure>
    <time_frame>within 7days before using Ginkgolides Meglumine Injectionand 3-10 days after using it.</time_frame>
    <description>Only the participants who are allergic to the main components of Ginkgolides Meglumine Injection will be assessed in 3-10 days after using it by the investigators..</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>0.1mg/ml Ginkgolides Meglumine Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection, 0.1mg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1mg/ml Ginkgolides Meglumine Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection, 1mg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg/ml Ginkgolides Meglumine Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection, 5mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1mg/ml Ginkgolides Meglumine Injection</intervention_name>
    <arm_group_label>0.1mg/ml Ginkgolides Meglumine Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg/ml Ginkgolides Meglumine Injection</intervention_name>
    <arm_group_label>1mg/ml Ginkgolides Meglumine Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5mg/ml Ginkgolides Meglumine Injection</intervention_name>
    <arm_group_label>5mg/ml Ginkgolides Meglumine Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female between the ages of 18 and 70(inclusive)at the time of signing the
             Informed Consent Form （ICF）.

          -  Subjects meet any one of the following requirements

               -  No history of using any dugs containing bilobalide, Ginkgolide A, Ginkgolide B,
                  Ginkgolide K (including Ginkgolides Meglumine Injection).

               -  History of using any dugs containing bilobalide, Ginkgolide A, Ginkgolide B,
                  Ginkgolide K (including Ginkgolides Meglumine Injection), and no allergy.

               -  History of allergy to any dugs contain bilobalide, Ginkgolide A, Ginkgolide B,
                  Ginkgolide K (including Ginkgolides Meglumine Injection).

               -  History of allergy to any other drugs.

          -  Willingness to participate in the study as evidenced by signing the informed consent
             form.

        Exclusion Criteria:

          -  Women in breastfeeding,menstrual or pregnancy period.

          -  Subjects are in the infectious disease, eczema, dermatitis, trauma,etc.

          -  Subjects meet any one of the following conditions

               -  Used β-blockers within 2 days prior to starting this study.

               -  Used H1 anti-histamines, imipramine, phenothiazine, Beta adrenaline etc. within 1
                  week prior to starting this study.

               -  Used short-acting glucocorticoids drugs within 1 week prior to starting this
                  study.

               -  Topical used glucocorticoids drugs within 2 weeks prior to starting this study.

               -  Used long-acting glucocorticoids drugs within 4 weeks prior to starting this
                  study

          -  Subjects are currently participating or have participated in any other clinical trials
             within the prior 1 month of signing the ICF.

          -  Subjects have a history of allergic shock.

          -  Subjects who are not suitable for this clinical trial at the discretion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuhong Huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Tianjin University of TCM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Tianjin University of TCM</name>
      <address>
        <city>Tianjin</city>
        <zip>300150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2014</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Skin test</keyword>
  <keyword>Ginkgolides Meglumine Injection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

